Skip to main content
SpringerLink
Log in

‘Pay attention’ to stimulants in attention-deficit hyperactivity disorder when other psychiatric disorders exist

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Pliszka SR. Psychiatric comorbidities in children with attention deficit hyperactivity disorder. Implications for management. Pediatr Drugs 2003; 5(11): 741–50

    Article  Google Scholar 

  2. MTA Cooperative Group. Moderators and mediators of treatment response for children with attention deficit hyperactivity disorder: the MTA study. Arch Gen Psychiatry 1999; 56: 1088–96

    Article  Google Scholar 

  3. Swanson J. Compliance with stimulants for attention-deficit/ hyperactivity disorder. Issues and approaches for improvement. CNS Drugs 2003; 17(2): 117–31

    Article  PubMed  Google Scholar 

  4. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41: 1026–36

    Article  PubMed  Google Scholar 

  5. Dunbar F, Kusumakar V, Daneman D, et al. Growth and sexual maturation in children are unaffected by long term treatment with risperidone. 49th meeting of the American Academy of Child and Adolescent Psychiatry; 2002 Oct 22–27; San Francisco

  6. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 1989; 28: 882–7

    Article  PubMed  CAS  Google Scholar 

  7. MTA Cooperative Group. 14 month randomized clinical trial of treatment strategies for children with attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999; 56(12): 1073–86

    Article  Google Scholar 

  8. Medicines and Healthcare Products Regulatory Agency. Safety review of antidepressants used by children completed (reference 2003/0505) [online]. Available from URL: http://www.mhra.gov.uk/news/ssri_101203.htm [Accessed 2004 Jun 21]

  9. US Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant medications [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm [Accessed 2004 Jun 21]

  10. Hughes CL, Emslie GJ, Crimson ML, et al. The Texas children’s medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 1999; 38(11): 1442–54

    Article  PubMed  CAS  Google Scholar 

  11. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–72

    Article  PubMed  CAS  Google Scholar 

  12. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001; 40: 307–14

    Article  PubMed  CAS  Google Scholar 

  13. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit-hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896–901

    Article  PubMed  Google Scholar 

  14. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention deficit-hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: 1–9

    Article  Google Scholar 

  15. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001; 40(10): 753–72

    Article  PubMed  CAS  Google Scholar 

  16. Sherman M, Hauser GC, Glover BH. Toxic reactions to tranylcypromine. Am J Psychiatry 1964: 120: 1019–21

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

‘Pay attention’ to stimulants in attention-deficit hyperactivity disorder when other psychiatric disorders exist. Drugs Ther. Perspect 20, 12–15 (2004). https://doi.org/10.2165/00042310-200420080-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200420080-00005

Search

Navigation